---
layout: post
title: New Drug Approvals 2012 - Pt. XII-pertuzumab (Perjetaâ„¢)
date: '2012-06-12T14:18:00.001+01:00'
author: Bissan Al-Lazikani
tags:
- mAb Drugs
- Black Box Warning Drugs
- 2012 New Drugs
modified_time: '2013-01-02T09:39:40.085Z'
thumbnail: http://1.bp.blogspot.com/-tunHiOaWQvc/UOQAVexJtWI/AAAAAAAAClg/eVtH9pHy4Ac/s72-c/perjeta-e1339339399552.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-1475245256364817995
blogger_orig_url: http://chembl.blogspot.com/2012/06/new-drug-approvals-2012-pt-xii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-tunHiOaWQvc/UOQAVexJtWI/AAAAAAAAClg/eVtH9pHy4Ac/s1600/perjeta-e1339339399552.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-tunHiOaWQvc/UOQAVexJtWI/AAAAAAAAClg/eVtH9pHy4Ac/s1600/perjeta-e1339339399552.jpg" /></a></div>
<center>
<br />
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/6,0,0,0,1,0,0,0,1" width="400" /><br />
</center>
<center>
<br /></center>
<br />
<div style="text-align: center;">
<b>ATC Code</b>: L01XC13
</div>
<div style="text-align: center;">
<b>Wikipedia</b>: <a href="http://en.wikipedia.org/wiki/Pertuzumab">Pertuzumab</a>
</div>
<br />
On June 8th 2012, the US FDA approved pertuzumab (also known as RG-1273 and RhuMAb-2C4, tradename: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=perjeta">Perjeta</a>) for the treatment of HER2/ERBB2 positive, late stage metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. <a href="http://en.wikipedia.org/wiki/Breast_cancer">Breast cancer </a>is the most common female cancer. About 20% of breast cancers have amplified and over expressed Epidermal Growth Factor Receptor 2 (EGFR2, a.k.a. ERBB2 and&nbsp;<a href="http://en.wikipedia.org/wiki/HER2/neu">HER2</a>). These cancer subtypes are associated with worse prognosis and higher metastatic rates. <br />
<br />
Pertuzumab is an anti-ERBB2/HER2  recombinant humanized monoclonal. It has been approved for use as part of a triple combination containing pertuzumab,    another anti-ERBB2/HER2 antibody, <a href="http://en.wikipedia.org/wiki/Trastuzumab">trastuzumab</a>, and the taxane <a href="http://en.wikipedia.org/wiki/Docetaxel">docetaxel</a>. The added value of combining both anti-ERBB2/HER2 antibodies is that pertuzumab binds to a different part of ERBB2 - the extracellular dimerization domain (Subdomain II) and this way it sterically blocks ligand-dependent  heterodimerization with other HER family members. Meanwhile, trastuzumab binds to and inhibits the juxtamembrane portion of the extracellular domain. <br />
Pertuzumab inhibits ligand-initiated intracellular signaling through the MAP kinase pathway, leading to cell growth arrest and the PI3 Kinase pathway, leading to apoptosis.<br />
<br />
<br />
<center>
<a href="http://3.bp.blogspot.com/-TnVSXuclwJA/T9cxqX90XBI/AAAAAAAAAJM/768gt-iiNvc/s1600/erbb_with_herceptin_nad_pertuzumab.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="318" src="http://3.bp.blogspot.com/-TnVSXuclwJA/T9cxqX90XBI/AAAAAAAAAJM/768gt-iiNvc/s320/erbb_with_herceptin_nad_pertuzumab.png" width="320" /></a><br />
<br />
<br />Superposition of the structures of pertuzumab (red) bound to ERBB2 (pink)- PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1s78/summary.html">1s78</a>,  with trastuzumab (blue) with ERBB2 (green) - PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1n8z/summary.html">1n8z</a>.<br />
</center>
<br />
<br />
Pertuzumab has been issued a Black Box Warning because it can cause embryo-fetal death and birth defects, and thus cannot be used by women who are pregnant.<br />
<br />
The target of pertuzumab is Human Epidermal Growth Factor Receptor 2 (ERBB2, HER2) (Uniprot:<a href="http://www.uniprot.org/uniprot/P04626">P04626</a>; ; chembl:<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1824">CHEMBL1824</a>; canSAR:<a href="https://cansar.icr.ac.uk/cansar/protein-targets/ERBB2-P04626/">ERBB2-P04626</a>). <br />
<br />
<pre>&gt;sp|P04626|ERBB2_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=1 SV=1
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
</pre>
<br />
Perjeta is marketed by <a href="http://www.gene.com/gene/news/press-releases/display.do?method=detail&amp;id=13847">Genentech Inc</a>, a member of the Roche group<br />
<br />
Full prescribing information can be obtained <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf">here</a>, and the product website <a href="http://www.perjeta.com/">here</a>.